Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)

Prospective, Non-Randomized, Observational, Multicentre, Study of the TVT Secur in the Surgical Management of Women With Stress Urinary Incontinence

This is a prospective, non-randomized, observational, multicentre (5 sites) study in which subjects that have surgically-correctable Stress Urinary Incontinence undergo a TVT SECUR operative procedure.

The study will collect preoperative urologic testing, medical history, and subject quality of life patient questionnaires, Intraoperative procedural data will be collected.

Postoperative complications, urologic, testing, and subject questionnaires will be collected at intervals up to 24 months. The anatomic position of the device will be characterize by transvaginal ultrasound testing.

To determine the rate and/or improvement rate of patients who have received the Gynecare Secur device after 12 months and after 24 months.

Study Overview

• Status: Terminated
• Conditions: Stress Urinary Incontinence
• Intervention / Treatment: Procedure: Gynecare TVT Secur

• Study Type: Observational
• Enrollment (Anticipated): 125

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M4N 3M5
      • Sunnybrook Health Sciences Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Approximately 125 women with SUI from 5 centres across Canada will participate in this study.

Description

Inclusion Criteria:

To be considered eligible to participate in this study, subjects must meet the following requirements:

1. Subject has agreed to undergo surgical implantation of the TVT SECUR System
2. Subject has the complaint of SUI for at least 6 months prior to the Preoperative Evaluation Visit.
3. Subject has confirmed SUI resulting from urethral hypermobility on cough stress testing.
4. Subject has at least 4 gm of urine leakage on 1-hour pad testing during the Preoperative Screening Visit.
5. Subject is at least 18 years of age to maximum of 85 years of age
6. Subject is willing and able to give written informed consent prior to any study related procedures.
7. Subject is willing to return for follow-up evaluation and questionnaire completion at 4-6 weeks, and at 3, 6, 12 and 24 month follow-ups.
8. Subject is willing to undergo transvaginal ultrasound evaluation at the 4 weeks and 12 month follow-up visit.

Exclusion Criteria:

Subjects will not be eligible for entry into the study if they meet one of the following criteria:

1. Subject is pregnant.
2. Subject has had any previous synthetic sub-urethral sling procedure.
3. Subject has current urinary tract or vaginal infections.
4. Subject has blood coagulation disorders.
5. Subject has a compromised immune system or any other conditions that would compromise healing.
6. Subject has upper urinary tract obstruction.
7. Subject is unwilling to provide written informed consent.
8. Subject is unwilling or unable to return for evaluation at 4-6 weeks, and at 3, 6, 12, and 24 months.
9. Subject has uncontrolled detrusor overactivity.
10. Subject has PVR greater than 100 cc.
11. Subject has Peak Flow Rate less than 10 ml/sec.
12. Subject has urethral diverticulum.
13. Subject has significant pelvic organ prolapse (Grade III/IV) requiring surgical treatment.
14. Subject has had radiation therapy to the pelvic area at any time.
15. Subject has current or active history of pelvic cancer.
16. Subject who in the opinion of the investigator is unable and/or unlikely to comprehend the nature, scope and possible consequences of the study and to follow the study procedures and instructions and complete all study related measurements.

Study Plan

How is the study designed?

Design Details

• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The primary endpoints are the cure/improvement rate in the cohort at 12 months.	12 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Distribution of percentage of subjects having a decrease of pad weight as compared to baseline	24 months
Decrease in number of pads used within a 24-hour period as compared to baseline	24 months
Change in patient questionnaires from baseline	24 months
Change in the sling position on transvaginal ultrasound	24 months
Cure/improvement rate at 24 months	24 months

Collaborators and Investigators

• Sponsor: Sunnybrook Health Sciences Centre
• Collaborators: Johnson & Johnson

Study record dates

Study Major Dates

• Study Start: September 1, 2009
• Primary Completion (Anticipated): September 1, 2012

Study Registration Dates

• First Submitted: October 19, 2009
• First Submitted That Met QC Criteria: December 8, 2009
• First Posted (Estimate): December 9, 2009

Study Record Updates

• Last Update Posted (Estimate): July 28, 2011
• Last Update Submitted That Met QC Criteria: July 27, 2011
• Last Verified: July 1, 2011

More Information

Terms related to this study

• Keywords: Stress Urinary Incontinence; SUI; Patients with Stress Urinary Incontinence
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Urologic Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Urination Disorders; Elimination Disorders; Urinary Incontinence; Enuresis; Urinary Incontinence, Stress
• Other Study ID Numbers: TVTSecur; 047-2009